Annals of the American Thoracic Society

Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer

Retrieved on: 
Monday, August 7, 2023

Dr. Lazarus brings valuable clinical and drug-development experience to the Avalyn executive team.

Key Points: 
  • Dr. Lazarus brings valuable clinical and drug-development experience to the Avalyn executive team.
  • "Howard’s appointment comes at a critical time in our clinical development," explained Lyn Baranowski , Avalyn’s CEO.
  • In that role, he diagnosed and treated patients with complex pulmonary vascular and interstitial diseases such as IPF and PAH.
  • I’m looking forward to working with the team to advance these product candidates into additional clinical trials and along their path towards approval by the regulatory agencies.”

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

Retrieved on: 
Thursday, May 18, 2023

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced data from its Phase 2 TORREY Study of seralutinib in patients with PAH will be featured in two sessions at the American Thoracic Society 2023 International Conference taking place in Washington D.C. from May 19-24.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced data from its Phase 2 TORREY Study of seralutinib in patients with PAH will be featured in two sessions at the American Thoracic Society 2023 International Conference taking place in Washington D.C. from May 19-24.
  • Dr. Robert Frantz, Director of the Pulmonary Hypertension Clinic and Professor of Medicine at Mayo Clinic will present the data on behalf of the TORREY Study investigators.
  • Presentation Title: Seralutinib Treatment in Adult Subjects with Pulmonary Arterial Hypertension: Results from the TORREY Study
    The presentation and poster will also be made available in the “Posters and Publications” section of the Gossamer Bio website at gossamerbio.com.
  • Following the positive results observed in the TORREY study and discussions with worldwide regulatory authorities, Gossamer plans to initiate a registrational Phase 3 clinical trial in patients with PAH in the third quarter of 2023.

Apnimed to Present Positive Phase 2b Results on AD109, an Investigational Oral Treatment for Obstructive Sleep Apnea, at ATS 2023

Retrieved on: 
Monday, May 15, 2023

A total of 294 participants with a wide range of OSA severity, from mild to severe (AHI4 of 10-45), were enrolled at 25 sites across the United States.

Key Points: 
  • A total of 294 participants with a wide range of OSA severity, from mild to severe (AHI4 of 10-45), were enrolled at 25 sites across the United States.
  • Participants were randomized to parallel arms comparing two doses of AD109, two doses of AD504 (a second candidate in an earlier phase of development), atomoxetine alone, and placebo.
  • MARIPOSA also incorporated other standard clinical endpoints designed to characterize improvement of oxygenation, sleep, and daytime function in OSA.
  • It is one of the largest clinical trials ever conducted of potential drug treatments designed to target the underlying cause of OSA.

Polarean to be a featured company at 2023 ATS Respiratory Innovation Summit

Retrieved on: 
Wednesday, May 3, 2023

Durham, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), the medical imaging technology company, has been selected as one of the featured companies as a poster presenter at the American Thoracic Society’s (“ATS”) 2023 Respiratory Innovation Summit (“RIS"), taking place 19-20 May in Washington D.C.

Key Points: 
  • Durham, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), the medical imaging technology company, has been selected as one of the featured companies as a poster presenter at the American Thoracic Society’s (“ATS”) 2023 Respiratory Innovation Summit (“RIS"), taking place 19-20 May in Washington D.C.
  • The Respiratory Innovation Summit unites innovators, investors, clinicians, and advocacy groups who work in the field of pulmonary medicine.
  • The meeting historically attracts more than 275 global leaders representing all facets of the respiratory industry, including start-ups, venture capital, government, academia, and clinicians.
  • Following the Respiratory Innovation Summit, Polarean will be exhibiting at the 2023 ATS International Conference, taking place 21-24 May.

Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis

Retrieved on: 
Monday, October 3, 2022

The manuscript in the Annals of the American Thoracic Society is available at (https://doi.org/10.1513/AnnalsATS.202103-348OC).

Key Points: 
  • The manuscript in the Annals of the American Thoracic Society is available at (https://doi.org/10.1513/AnnalsATS.202103-348OC).
  • This multicenter, double-blind, randomized-controlled study enrolled 89 patients under the age of 12 months who were hospitalized with moderate-severe bronchiolitis.
  • The patients were randomized equally across three arms: standard supportive therapy (SST); 85 ppm NO + SST and 150 ppm NO + SST.
  • The primary endpoint was time to fit-to-discharge (FTD), a composite of the modified TAL score and sustained oxygen saturation on room air.

Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 15, 2022

WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2022.

Key Points: 
  • WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2022.
  • REBUILD Phase 3 Study: Enrollment is continuing in Bellerophons Phase 3 REBUILD registrational study of INOpulse for the treatment of fILD.
  • The Phase 3 program builds on positive top-line results from the Companys previously reported Phase 2 studies for INOpulse for the treatment of fILD.
  • The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein

Retrieved on: 
Thursday, July 7, 2022

Lenzilumab binds to and neutralizes GM-CSF, potentially improving outcomes for patients hospitalized with COVID-19.

Key Points: 
  • Lenzilumab binds to and neutralizes GM-CSF, potentially improving outcomes for patients hospitalized with COVID-19.
  • Humanigens Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19.
  • C-reactive protein, a biomarker for early lenzilumab treatment of COVID-19, improves efficacy: a sub-analysis of the randomized phase 3 LIVE-AIR trial.
  • https://doi.org/10.1016/S2213-2600(21)00494-X
    Humaneered is a trademark of Humanigen, Inc.
    Yescarta and Tecartus are trademarks of Gilead Sciences, Inc., or its related companies.

FreeStyle® Comfort® Excels in POC Comparison Study

Retrieved on: 
Wednesday, March 30, 2022

CAIREs premier portable oxygen concentrator, the FreeStyle Comfort, outperformed other market leading devices in a recent study designed to assess the effectiveness of these devices in delivering oxygen to patients.

Key Points: 
  • CAIREs premier portable oxygen concentrator, the FreeStyle Comfort, outperformed other market leading devices in a recent study designed to assess the effectiveness of these devices in delivering oxygen to patients.
  • The GSU study demonstrated the CAIRE FreeStyle Comfort achieved higher FiO2 compared to all other POCs in seven out of the eight scenarios.
  • Introduced in 2018, the FreeStyle Comfort has earned recognition from its peers, and has been distributed to hundreds of thousands oxygen users globally.
  • This study confirms that the FreeStyle Comfort meets those objectives ensuring patients get the oxygen they need when they need it.

Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis

Retrieved on: 
Tuesday, December 14, 2021

(Nasdaq: VCYT) announced today the publication of clinical utility data confirming the ability of the Envisia Genomic Classifier to improve diagnostic and treatment decision-making for patients with idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • (Nasdaq: VCYT) announced today the publication of clinical utility data confirming the ability of the Envisia Genomic Classifier to improve diagnostic and treatment decision-making for patients with idiopathic pulmonary fibrosis (IPF).
  • The Envisia classifier is a highly accurate, clinically validated molecular test that detects a genomic pattern of usual interstitial pneumonia (UIP), a critical factor that can help physicians differentiate IPF from other ILDs.
  • Our findings demonstrate the clinical utility of the Envisia classifier by increasing the number of IPF diagnoses and associated confidence in those diagnoses, while avoiding more-invasive procedures.
  • Examples of forward-looking statements include, among others, statements regarding Veracytes belief that its Envisia Genomic Classifier can significantly improve the diagnosis of ILDs, including IPF, and assist healthcare providers in selecting patient treatment options.

Inspira Technologies: Professor Eddy Fan, Expert in Critical Care Medicine and Extracorporeal Support, Joins Inspira's Scientific Advisory Board

Retrieved on: 
Tuesday, November 30, 2021

Ltd.(Nasdaq: IINN) (Nasdaq: IINNW)(the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that Proffesor Eddy Fan, an expert in critical care and extracorporeal life support methods, has joined Inspira Technologies' Scientific Advisory Board.

Key Points: 
  • Ltd.(Nasdaq: IINN) (Nasdaq: IINNW)(the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that Proffesor Eddy Fan, an expert in critical care and extracorporeal life support methods, has joined Inspira Technologies' Scientific Advisory Board.
  • Fan currently holds the medical director of the extracorporeal life support program at the Toronto General Hospital.
  • JAMA"
    Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries.
  • Dagi Ben-Noon, Inspira Technologies' Chief Executive Officer,stated: "We are honored to have Professor Fan on Inspira Technologies' Scientific Advisory Board.